Key points are not available for this paper at this time.
Background and objectives: SLTRiP) formulated with a dual toll-like receptor (TLR) adjuvant combination, Poly(I:C) and R848, to evaluate the potency and durability of the elicited humoral response. Methods: SLTRiP, either alone or in combination (Poly(I:C) and R848). Humoral immune responses were quantified 30-80 days post-immunization through total IgG kinetics, functional IgG isotypes (IgG1, IgG2c/IgG2a), and antibody avidity (AI). Results: SLTRiP immunization, however, produced progressive increases in total IgG, detectable IgG2c responses, and modest changes in antibody avidity, with little non-significant difference between adjuvant regimens. Conclusions: T-cell cross-presentation.
Tandel et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: